Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 2,96 € (+228,89%). La mediana è 2,96 € (+228,89%).

Acquista
  6
Mantieni
  1
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Product recall weighs on Biote Q1: profit and revenue below expectations

    Biote reports Q1 2026 EPS of $0.06 (expectation $0.10) and revenue of $44.9m (expectation $46.01m), mainly impacted by a voluntary recall of bioidentical hormone pellets. Revenue fell 8.3% year over year, treatment revenues declined 13.2%, while supplements rose 19.1% thanks to e‑commerce. The stock fell 5.43% in after‑hours trading. Despite the disruption, management reaffirms the full‑year guidance of >$190m in revenue and >$38m in adjusted EBITDA and expects a recovery in the second half of the year. » Altro su de.investing.com


  • Biote misses Q1 forecasts: EPS and revenue fall short of expectations

    Biote reported Q1 2026 earnings of $0.06 per share versus $0.10 expected and revenue of $44.9 million versus $46.01 million expected. Revenue fell 8.3% year‑on‑year, weighed down by a voluntary recall of bioidentical hormone pellets, while the supplements segment grew 19.1%. Management maintains its full‑year revenue guidance of over $190 million and expects treatment revenues to recover in the second half of the year. After the release, the stock fell 0.45% to $2.21. » Altro su de.investing.com


  • Biote Corp misses Q4 2025 earnings forecast and reports revenue decline

    Biote Corp reported Q4 2025 EPS of $0.06, missing the $0.09 estimate; revenue was $46.4 million, slightly below the expected $47.12 million. The supplement business grew 16% thanks to e‑commerce, but could not offset declines in treatment revenue and higher clinic churn. Gross margin fell due to inventory charges following a recall; the company expects treatment revenue headwinds through the first half of 2026 and growth in the supplement segment later in the year. » Altro su de.investing.com


  • Biote Corp. subsidiary Asteria Health recalls hormone pellets over metal particle risk

    Biote Corp. said its subsidiary F.H. Investments, operating as Asteria Health, has initiated a voluntary recall of certain batches of compounded bioidentical hormone pellets shipped between May 20, 2025 and January 19, 2026. The recall is due to potential contamination with metal particles and is being conducted with knowledge of the FDA. Biote expects a one‑time charge of about $1.3 million in the fourth quarter for write‑down of affected inventory and estimates additional recall costs for 2026 of roughly $1 million. The company does not expect significant further impact on supply to partner clinics and will disclose details of the financial effects with its Q4 results. » Altro su de.investing.com


  • biote posts Q3 EPS 371% above forecasts; analysts trim 2026 EPS and price target

    biote reported Q3 revenue of US$48m in line with expectations and statutory EPS of US$0.22, 371% above forecasts. After the results analysts left 2026 revenue estimates roughly unchanged at US$198.4m but cut consensus EPS to US$0.32 from US$0.34. The average price target fell 5.6% to US$4.61, and analysts now expect biote’s revenue growth to slow materially below industry peers. » Altro su finance.yahoo.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Biote Corp ha registrato ricavi pari a 38,26 Mln € e un utile netto di 359,32K €
(EUR) settembre 2026
YoY
Ricavi 38,26 Mln 6,38%
Utile lordo 25,89 Mln 11,71%
Utile netto 359,32K 94,85%
EBITDA 3,98 Mln 61,49%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
39,79 Mln €
Numero di azioni
44,11 Mln
Massimo/minimo a 52 settimane
2,64 € - 0,87 €
Dividendi No
Beta
1,74
Rapporto P/E
-12,84
Rapporto PEG
0,12
Rapporto P/B
-0,41
Rapporto P/S
0,24

Profilo aziendale

Biote Corp. opera nel settore della gestione di studi medici nell'ambito dell'ottimizzazione ormonale. L'azienda offre una piattaforma che consente ai professionisti certificati Biote di ottimizzare gli squilibri nei livelli ormonali, vitaminici e minerali dei propri pazienti, nonché di prescrivere terapie ormonali bioidentiche e raccomandare integratori alimentari. Inoltre, vende integratori alimentari a marchio Biote e kit sterili per l'inserimento di pellet destinati a uomini e donne. La società è stata fondata nel 2011 ed ha sede a Irvine, in Texas.

Nome
Biote Corp
CEO
Robert C. Peterson
Sede centrale Irving, tx
Stati Uniti
Sito web
Settore
Sanità
Industria
Fornitori e servizi sanitari
Quotazione in borsa
28/04/2021
Dipendenti 223

Simboli di borsa

Borsa Simbolo
Pnk
BTMD
🍪

Parqet  usa i cookie. Scopri di più